ITMI20021205A0 - Uso di proteine per il trattamento della leishmaniosi - Google Patents

Uso di proteine per il trattamento della leishmaniosi

Info

Publication number
ITMI20021205A0
ITMI20021205A0 IT2002MI001205A ITMI20021205A ITMI20021205A0 IT MI20021205 A0 ITMI20021205 A0 IT MI20021205A0 IT 2002MI001205 A IT2002MI001205 A IT 2002MI001205A IT MI20021205 A ITMI20021205 A IT MI20021205A IT MI20021205 A0 ITMI20021205 A0 IT MI20021205A0
Authority
IT
Italy
Prior art keywords
leishmaniasis
proteins
treatment
Prior art date
Application number
IT2002MI001205A
Other languages
English (en)
Inventor
Pierferdinando Nicoletti
Antonio Salvaggio
Battesimo Macri
Original Assignee
Pharmaproducts Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaproducts Uk Ltd filed Critical Pharmaproducts Uk Ltd
Priority to IT2002MI001205A priority Critical patent/ITMI20021205A1/it
Publication of ITMI20021205A0 publication Critical patent/ITMI20021205A0/it
Priority to AT03732475T priority patent/ATE306279T1/de
Priority to MXPA04012050A priority patent/MXPA04012050A/es
Priority to AU2003238407A priority patent/AU2003238407A1/en
Priority to JP2004508832A priority patent/JP2005529932A/ja
Priority to BR0311596-8A priority patent/BR0311596A/pt
Priority to DE60301886T priority patent/DE60301886D1/de
Priority to US10/516,465 priority patent/US20060100142A1/en
Priority to EP03732475A priority patent/EP1511510B1/en
Priority to PCT/EP2003/005551 priority patent/WO2003101477A1/en
Publication of ITMI20021205A1 publication Critical patent/ITMI20021205A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT2002MI001205A 2002-06-04 2002-06-04 Uso di proteine per il trattamento della leishmaniosi ITMI20021205A1 (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IT2002MI001205A ITMI20021205A1 (it) 2002-06-04 2002-06-04 Uso di proteine per il trattamento della leishmaniosi
PCT/EP2003/005551 WO2003101477A1 (en) 2002-06-04 2003-05-27 Use of uk114 in the treatment of leishmaniasis
JP2004508832A JP2005529932A (ja) 2002-06-04 2003-05-27 リーシュマニア症の治療におけるｕｋ１１４の使用
MXPA04012050A MXPA04012050A (es) 2002-06-04 2003-05-27 Uso de uk114 en el tratamiento de lishmaniasis.
AU2003238407A AU2003238407A1 (en) 2002-06-04 2003-05-27 Use of uk114 in the treatment of leishmaniasis
AT03732475T ATE306279T1 (de) 2002-06-04 2003-05-27 Verwendung von uk114 für die behandlung von leishmaniasis
BR0311596-8A BR0311596A (pt) 2002-06-04 2003-05-27 Uso de uk114 no tratamento de leishmaniose
DE60301886T DE60301886D1 (de) 2002-06-04 2003-05-27 Verwendung von uk114 für die behandlung von leishmaniasis
US10/516,465 US20060100142A1 (en) 2002-06-04 2003-05-27 Use of uk114 in the treatment of leishmaniasis
EP03732475A EP1511510B1 (en) 2002-06-04 2003-05-27 Use of uk114 in the treatment of leishmaniasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI001205A ITMI20021205A1 (it) 2002-06-04 2002-06-04 Uso di proteine per il trattamento della leishmaniosi

Publications (2)

Publication Number Publication Date
ITMI20021205A0 true ITMI20021205A0 (it) 2002-06-04
ITMI20021205A1 ITMI20021205A1 (it) 2003-12-04

Family

ID=11450033

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI001205A ITMI20021205A1 (it) 2002-06-04 2002-06-04 Uso di proteine per il trattamento della leishmaniosi

Country Status (10)

Country Link
US (1) US20060100142A1 (it)
EP (1) EP1511510B1 (it)
JP (1) JP2005529932A (it)
AT (1) ATE306279T1 (it)
AU (1) AU2003238407A1 (it)
BR (1) BR0311596A (it)
DE (1) DE60301886D1 (it)
IT (1) ITMI20021205A1 (it)
MX (1) MXPA04012050A (it)
WO (1) WO2003101477A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024074870A1 (es) * 2022-10-06 2024-04-11 Instituto Politecnico Nacional Composición veterinaria de péptidos para inmunoterapia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1290828B1 (it) * 1997-03-25 1998-12-11 Zetesis Spa Uso di proteine estraibili da organi animali per la preparazione di medicamenti per il trattamento di condizioni patologiche
IT1298442B1 (it) * 1998-02-24 2000-01-10 Zetesis Spa Composizioni orali a basso dosaggio di proteine citotossiche
ITMI991384A1 (it) * 1999-06-22 2000-12-22 Zetesis Spa Uso della proteina uk 114 per inibire il rigetto dei trapianti d'organo

Also Published As

Publication number Publication date
BR0311596A (pt) 2005-04-26
AU2003238407A1 (en) 2003-12-19
EP1511510B1 (en) 2005-10-12
US20060100142A1 (en) 2006-05-11
WO2003101477A1 (en) 2003-12-11
DE60301886D1 (de) 2006-02-23
JP2005529932A (ja) 2005-10-06
EP1511510A1 (en) 2005-03-09
ATE306279T1 (de) 2005-10-15
ITMI20021205A1 (it) 2003-12-04
MXPA04012050A (es) 2005-09-08

Similar Documents

Publication Publication Date Title
DE60217294D1 (de) Hauteinschnittblutentnahmegerät
NO20034439L (no) Benzamidinderivater
NO20034176D0 (no) Pyrazolopyrimidiner som terapeutiske midler
NO20034177L (no) Pyrazolopyrimidiner som terapeutiske midler
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
EP1460900A4 (en) Human secreted proteins
ITMI20021038A0 (it) Disposizione di elettrodi
DE60212783D1 (de) Tragstruktur
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
ITRM20010708A0 (it) Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
ITMI20010954A0 (it) Procedimento di iodurazione
ITRM20030178A1 (it) Uso della l-carnitina per il trattamento di patologie cardiovascolari.
ITMI20021205A0 (it) Uso di proteine per il trattamento della leishmaniosi
ITMI20031994A1 (it) Procedimento per la preparazione di fludarabina fosfato
ES1052302Y (es) Soporte de suministros medicos.
ATA5002002A (de) Vibrator
ITMI20022308A1 (it) Proteine per il trattamento di neutropenie.
DE60220421D1 (de) Körperstütze
DE10157913B4 (de) Therapietisch
ITMI20012131A0 (it) Procedimento per la preparazione di alo-benzonitrili
ITMI20020620A1 (it) Procedimento per la preparazione di alchil-benzoati per esterificazione di benzoil-fluoruri
SE0101506L (sv) Växlad rullstol
ES1050717Y (es) Soporte para bandejas portacables-
SE0101231D0 (sv) Novel use of proton pump inhibitors
ITMI20022371A1 (it) Kit per il montaggio di paralumi cilindrici decorati costruiti in